icrf 198 has been researched along with razoxane in 19 studies
| Studies (icrf 198) | Trials (icrf 198) | Recent Studies (post-2010) (icrf 198) | Studies (razoxane) | Trials (razoxane) | Recent Studies (post-2010) (razoxane) |
|---|---|---|---|---|---|
| 24 | 0 | 4 | 824 | 115 | 56 |
| Protein | Taxonomy | icrf 198 (IC50) | razoxane (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 10 (52.63) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vile, GF; Winterbourn, CC | 1 |
| Hasinoff, BB | 4 |
| Ferrans, VJ; Fukuda, Y; Hasinoff, BB; Herman, EH; Raley, LG; Zhang, J; Zhang, TM | 1 |
| Hasinoff, BB; Malisza, KL | 1 |
| Buss, JL; Hasinoff, BB | 1 |
| Thomas, C; Vile, GF; Winterbourn, CC | 1 |
| Allan, WP; Creighton, AM; Fattman, CL; Hasinoff, BB; Kuschak, TI; Thampatty, P; Yalowich, JC | 1 |
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Boehme, P; Gordeuk, VR; John, C; Loyevsky, M; Sacci, JB; Weglicki, W | 1 |
| Boroujerdi, M; Vaidyanathan, S | 1 |
| Hasinoff, BB; Schroeder, PE | 2 |
| Hasinoff, BB; Hofland, KF; Jensen, PB; Langer, SW; Schroeder, PE; Sehested, M | 1 |
| Hasinoff, BB; Patel, D | 1 |
| Hrušková, K; Klimeš, J; Kovaříková, P; Stariat, J; Vávrová, K | 1 |
| Klimes, J; Kovarikova, P; Pasakova-Vrbatova, I; Simunek, T; Stariat, J; Vavrova, A | 1 |
19 other study(ies) available for icrf 198 and razoxane
| Article | Year |
|---|---|
dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Topics: Animals; Calcium-Transporting ATPases; Chelating Agents; Cytochrome c Group; Doxorubicin; Ethylenediamines; Ferric Compounds; Glycine; Kinetics; Lipid Peroxidation; Microsomes; Myocardium; NADP; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Piperazines; Rabbits; Razoxane; Stereoisomerism | 1990 |
The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
Topics: Cardiotonic Agents; Chelating Agents; Copper; Doxorubicin; Electron Transport Complex IV; Ethylenediamines; Glycine; Iron; Organometallic Compounds; Piperazines; Razoxane; Stereoisomerism; Submitochondrial Particles | 1989 |
Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity.
Topics: Animals; Bleomycin; Ethylenediamines; Female; Glycine; Iron; Lung; Lung Diseases; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Razoxane; Spectrophotometry | 1995 |
NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
Topics: Animals; Catalase; Chelating Agents; Edetic Acid; Electron Spin Resonance Spectroscopy; Ethylenediamines; Glycine; Hydroxyl Radical; Iron Chelating Agents; Models, Chemical; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Rats; Razoxane; Spectrophotometry, Ultraviolet | 1995 |
Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Topics: Aerobiosis; Antibiotics, Antineoplastic; Antioxidants; Chelating Agents; Doxorubicin; Electron Spin Resonance Spectroscopy; Ethylenediamines; Ferric Compounds; Ferrous Compounds; Glycine; Heart; Hydrolysis; Hydroxyl Radical; Mitoxantrone; Models, Chemical; Oxidation-Reduction; Razoxane | 1995 |
Quantitation of the dexrazoxane hydrolysis product ADR-925 by fluorescence detection of its terbium(III) complex after high-performance liquid chromatographic separation.
Topics: Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Glycine; Humans; Razoxane; Spectrometry, Fluorescence; Terbium | 1994 |
The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
Topics: Anthracenes; Ethylenediamines; Glycine; Hydrolysis; Iron; Kinetics; Models, Molecular; Razoxane; Spectrophotometry, Infrared | 1993 |
The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Topics: Ascorbic Acid; Chelating Agents; Deoxyribose; Dimethyl Sulfoxide; Doxorubicin; Edetic Acid; Ethylenediamines; Ferric Compounds; Glycine; Hydrogen Peroxide; Hydrolysis; Hydroxides; Hydroxyl Radical; Iron; Kinetics; Oxidation-Reduction; Paraquat; Razoxane; Superoxides; Thiobarbituric Acid Reactive Substances; Xanthine Oxidase | 1993 |
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Topics: Aclarubicin; Animals; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance; Ethylenediamines; Etoposide; Glycine; Mutation; Razoxane; Thiobarbiturates; Topoisomerase II Inhibitors; Verapamil | 1997 |
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Deferoxamine; Erythrocytes; Ethylenediamines; Ferrous Compounds; Fluoresceins; Fluorescent Dyes; Glycine; Humans; Iron Chelating Agents; Liver; Malaria, Falciparum; Mice; Microscopy, Fluorescence; Parasitemia; Plasmodium falciparum; Plasmodium yoelii; Prodrugs; Quaternary Ammonium Compounds; Razoxane; Spectrometry, Fluorescence; Surface Properties | 1999 |
Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Topics: Animals; Chelating Agents; Doxorubicin; Endothelins; Erythrocyte Membrane; Erythrocytes; Ethylenediamines; Female; Glycine; Hemoglobins; Kinetics; Rats; Rats, Sprague-Dawley; Razoxane | 2000 |
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure | 2002 |
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Ethylenediamines; Etoposide; Female; Glycine; Half-Life; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Razoxane | 2003 |
Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Topics: Amidohydrolases; Animals; Brain; Cardiotonic Agents; Chelating Agents; Dihydroorotase; Ethylenediamines; Glycine; Hepatocytes; Liver; Male; Myocardium; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane | 2005 |
The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cells, Cultured; Cytoprotection; Doxorubicin; Ethylenediamines; Glycine; Iron Chelating Agents; L-Lactate Dehydrogenase; Myocytes, Cardiac; Pyridines; Rats; Rats, Sprague-Dawley; Razoxane; Thiosemicarbazones | 2009 |
Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites--the cardioprotectant dexrazoxane as a model case.
Topics: Cardiovascular Agents; Chromatography, Liquid; Ethylenediamines; Glycine; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Models, Chemical; Razoxane; Tandem Mass Spectrometry; Temperature | 2011 |
Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.
Topics: Animals; Animals, Newborn; Cardiovascular Agents; Cells, Cultured; Chromatography, Liquid; Ethylenediamines; Glycine; Myocytes, Cardiac; Pilot Projects; Rabbits; Rats; Rats, Wistar; Razoxane; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |